Arrowhead Pharmaceuticals reported fiscal 2026 first‑quarter revenue of $264.0 million, a dramatic increase from $2.5 million in the same period a year earlier. Net income rose to $30.8 million, or $0.22 per share, turning a $173.1 million loss in Q1 FY2025 into a profitable quarter and beating consensus earnings estimates of $0.12 to $0.60 per share.
Revenue growth was largely powered by milestone and royalty payments from key partnerships. Sarepta contributed $229 million and Novartis added $34 million, while the company’s first commercial sales of REDEMPLO for familial chylomicronemia syndrome generated early revenue and over 100 prescriptions in the first 10 weeks of launch.
The results represent a sharp turnaround from the prior year’s $173.1 million net loss and $2.5 million revenue. EPS of $0.22 surpassed the consensus range of $0.12–$0.60, a beat of $0.10–$0.08 per share, driven by strong partnership cash flow and the initial commercial traction of REDEMPLO.
CEO Christopher Anzalone highlighted the company’s “historic period” and the successful launch of REDEMPLO, noting that the company is now “well positioned to build on this progress throughout 2026 and beyond.” CFO Daniel Apel emphasized that the $30.8 million net income reflects disciplined cost management and the monetization of the company’s platform assets.
Investors reacted with caution, citing concerns over Arrowhead’s forward‑looking guidance that signals potential future losses and questions about the long‑term scalability of REDEMPLO. The market’s focus on guidance underscores the need for sustained profitability beyond the current quarter’s strong performance.
The earnings turnaround confirms Arrowhead’s shift from a cash‑burning R&D model to a capital‑generating platform. With a cash balance of $917 million and ongoing pipeline development, the company is positioned to fund future growth, but it must demonstrate continued profitability to satisfy investor expectations.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.